Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bassam Mattar (NPI 1053372649)

Field	Value
Entity Type	Individual
Organization	Bassam Mattar
Address	818 N Emporia St
City	Wichita
State	KS
ZIP	67214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 31, 2006

Payer Source	Total Paid
Medicare	$7.2M
Medicaid	$0

Key Findings

Provider profile and payer mix: BASSAM MATTAR is a Hematology & Oncology Physician in WICHITA, KS with an NPI enumerated 2006-03-31 (~20 years ago). Lifetime billing shows $7.2M in Medicare revenue and no Medicaid billing on file, indicating this practice operates effectively as a Medicare-focused single-payer operation in our dataset.

Service-line characterization: The revenue and code mix indicate an infusion-centered oncology practice with heavy use of immune checkpoint inhibitors and other biologic agents. High-revenue drug codes such as J9271 (pembrolizumab), J9299 (nivolumab), and J0897 (denosumab) dominate the portfolio, supported by chemo administration (96413), infusion add-ons (96367), and imaging (78815) consistent with active systemic oncology care.

Revenue concentration: The top three Medicare codes account for 48.0% of this provider's total Medicare revenue, with J9271 at $1.6M (23.8%), J9299 at $914.9K (13.6%), and J0897 at $713.9K (10.6%). This concentration shows a majority of revenue is driven by a small set of high-cost injectable oncology agents.

Competitive standing on key drugs: For several primary drugs this provider ranks well above peers nationally — J9271 ranks #44 of 1841 providers nationally (98th percentile; notably above typical national volume) and J9299 ranks #32 of 505 providers nationally (94th percentile; notably above typical national volume). J0897 is listed as an extreme outlier (rank #45 of 10057 providers nationally; 100th percentile), signaling exceptionally high national volume for denosumab relative to peers.

Utilization and visit mix: The practice also reports substantial office and procedural activity beyond drug administration: 99214 generated $173.9K (2.6% of Medicare revenue) and ranks #1569 of 479517 providers nationally (100th percentile; extreme outlier), while 96413 generated $139K (2.1%) and ranks #16 of 7514 providers nationally (100th percentile; extreme outlier). These patterns point to a steady stream of moderate-complexity E&M visits paired with high chemotherapy/infusion throughput.

Other notable outliers and high-volume generics/biosimilars: Several additional codes are flagged as unusually high volume — J0185 (aprepitant) shows 42K claims and $42K revenue and ranks #3 of 819 providers nationally (100th percentile; extreme outlier), 96367 ranks #50 of 4032 providers nationally (99th percentile; extreme outlier), and J1627 ranks #3 of 119 providers nationally (98th percentile; notably above typical national volume). These data suggest extensive supportive-care and antiemetic administration alongside primary oncology therapeutics.

Operational scale indicators: Claim-level volumes for key codes are large (e.g., 37.2K claims for J9271, 39.8K claims for J9299, 39.7K claims for J0897), reinforcing that this is a high-throughput infusion practice rather than a low-volume specialist. Combined with long tenure (NPI enumerated 2006-03-31 (~20 years ago)), the data point to an established, high-volume oncology operator focused on Medicare beneficiaries.

Commercial implications and payer exposure: With $7.2M in Medicare revenue and no Medicaid billing on file, the provider’s financial performance and contracting leverage will be driven primarily by Medicare reimbursement patterns and provider-level utilization of high-cost oncology injectables. Concentration in a few high-revenue injectable agents creates both negotiating focus points (those agents and associated infusion services) and exposure if use patterns or reimbursement for those agents change.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

119 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	37,200	$40	$1.6M
J9299	Injection, nivolumab, 1 mg	39,780	$20	$914.9K
J0897	Injection, denosumab, 1 mg	39,660	$20	$713.9K
J9022	Injection, atezolizumab, 10 mg	8,280	$60	$529.9K
J1930	Injection, lanreotide, 1 mg	9,600	$40	$422.4K
J9145	Injection, daratumumab, 10 mg	8,190	$50	$384.9K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,740	$40	$301.9K
J9228	Injection, ipilimumab, 1 mg	2,150	$130	$281.6K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	6,480	$30	$220.3K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	8,960	$20	$206.1K

Showing 1–10 of 119

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 119 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Bassam Mattar — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

119 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	20	28,900	$40	$1.1M
J9299	2	10	24,550	$20	$637.2K
J1930	2	10	9,180	$40	$402.7K
J9145	4	10	6,660	$50	$394.7K
J9022	1	10	3,910	$60	$301.1K
J9228	1	10	2,150	$130	$281.6K
J9144	3	10	6,300	$40	$257.2K
J1568	1	10	3,690	$30	$129K
Q5107	1	10	4,440	$20	$106.5K
Q5115	3	10	2,340	$30	$92.9K

Showing 1–10 of 119

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bassam Mattar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0
Shaker Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Bassam Mattar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Craig Resources LLC	KS	Home Health Agency	$0	$97.3M
Paradigm Services Inc	KS	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$42.4M
Wesley Medical Center LLC	KS	General Acute Care Hospital	$0	$30.2M
Gracemed Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$18.3M
Healthcore Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$15.3M
Diversified Family Services LLC	KS	Home Health Agency	$0	$13.9M
Alpha Service	KS	Developmentally Disabled Services Day Training Agency	$0	$12.1M
Carepoint Emergency Medicine Kansas LLC	KS	Emergency Medicine Physician	$0	$11.8M
Hunter Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$10.4M
Ascension Via Christi Hospitals Wichita Inc.	KS	General Acute Care Hospital	$0	$8.9M

Bassam Mattar — Billing Profile & Reimbursement Data

Sign up for Bassam Mattar — Billing Profile & Reimbursement Data policy alerts

Bassam Mattar — Billing Profile & Reimbursement Data

Sign up for Bassam Mattar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References